These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 24689911)

  • 1. Regular exercise coupled to diet regimen accelerates reduction of hepatic steatosis and associated pathological conditions in nonalcoholic fatty liver disease.
    Oh S; Tanaka K; Tsujimoto T; So R; Shida T; Shoda J
    Metab Syndr Relat Disord; 2014 Jun; 12(5):290-8. PubMed ID: 24689911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.
    de Piano A; de Mello MT; Sanches Pde L; da Silva PL; Campos RM; Carnier J; Corgosinho F; Foschini D; Masquio DL; Tock L; Oyama LM; do Nascimento CM; Tufik S; Dâmaso AR
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1313-24. PubMed ID: 22932160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise reduces inflammation and oxidative stress in obesity-related liver diseases.
    Oh S; Tanaka K; Warabi E; Shoda J
    Med Sci Sports Exerc; 2013 Dec; 45(12):2214-22. PubMed ID: 23698242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
    Copaci I; Lupescu I; Caceaune E; Chiriac G; Ismail G
    Rom J Intern Med; 2015; 53(1):54-62. PubMed ID: 26076562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoadiponectinaemia in nonalcoholic fatty liver disease obese women is associated with infrequent intake of dietary sucrose and fatty foods.
    Magalhães GC; Feitoza FM; Moreira SB; Carmo AV; Souto FJ; Reis SR; Martins MS; Gomes da Silva MH
    J Hum Nutr Diet; 2014 Apr; 27 Suppl 2():301-12. PubMed ID: 23790128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study.
    Oh S; Shida T; Yamagishi K; Tanaka K; So R; Tsujimoto T; Shoda J
    Hepatology; 2015 Apr; 61(4):1205-15. PubMed ID: 25271091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors.
    Jin YJ; Kim KM; Hwang S; Lee SG; Ha TY; Song GW; Jung DH; Kim KH; Yu E; Shim JH; Lim YS; Lee HC; Chung YH; Lee Y; Suh DJ
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1341-7. PubMed ID: 22554085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
    Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH
    Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.
    Da Silva HE; Arendt BM; Noureldin SA; Therapondos G; Guindi M; Allard JP
    J Acad Nutr Diet; 2014 Aug; 114(8):1181-94. PubMed ID: 24631112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children.
    Grønbæk H; Lange A; Birkebæk NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Vilstrup H
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):223-8. PubMed ID: 21760546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease.
    Abenavoli L; Luigiano C; Guzzi PH; Milic N; Morace C; Stelitano L; Consolo P; Miraglia S; Fagoonee S; Virgilio C; Luzza F; De Lorenzo A; Pellicano R
    Panminerva Med; 2014 Jun; 56(2):189-93. PubMed ID: 24994581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
    J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
    Musso G; Gambino R; Bo S; Uberti B; Biroli G; Pagano G; Cassader M
    Diabetes Care; 2008 Mar; 31(3):562-8. PubMed ID: 18056890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
    Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
    Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.